GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sonnet BioTherapeutics Holdings Inc (NAS:SONN) » Definitions » Pretax Margin %

Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Pretax Margin % : % (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sonnet BioTherapeutics Holdings Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Sonnet BioTherapeutics Holdings's Pre-Tax Income for the three months ended in Mar. 2024 was $0.37 Mil. Sonnet BioTherapeutics Holdings's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Sonnet BioTherapeutics Holdings's pretax margin for the quarter that ended in Mar. 2024 was %.

The historical rank and industry rank for Sonnet BioTherapeutics Holdings's Pretax Margin % or its related term are showing as below:

SONN' s Pretax Margin % Range Over the Past 10 Years
Min: -12725   Med: -8492   Max: -5161.98
Current: -9062.37


SONN's Pretax Margin % is ranked worse than
89.68% of 1027 companies
in the Biotechnology industry
Industry Median: -155.32 vs SONN: -9062.37

Sonnet BioTherapeutics Holdings Pretax Margin % Historical Data

The historical data trend for Sonnet BioTherapeutics Holdings's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonnet BioTherapeutics Holdings Pretax Margin % Chart

Sonnet BioTherapeutics Holdings Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
Pretax Margin %
- - -5,161.98 -8,492.00 -12,725.00

Sonnet BioTherapeutics Holdings Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15,741.67 -10,667.57 -9,937.84 -6,152.63 -

Competitive Comparison of Sonnet BioTherapeutics Holdings's Pretax Margin %

For the Biotechnology subindustry, Sonnet BioTherapeutics Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonnet BioTherapeutics Holdings's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sonnet BioTherapeutics Holdings's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Sonnet BioTherapeutics Holdings's Pretax Margin % falls into.



Sonnet BioTherapeutics Holdings Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Sonnet BioTherapeutics Holdings's Pretax Margin for the fiscal year that ended in Sep. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Sep. 2023 )/Revenue (A: Sep. 2023 )
=-18.833/0.148
=-12,725.00 %

Sonnet BioTherapeutics Holdings's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=0.365/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sonnet BioTherapeutics Holdings  (NAS:SONN) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Sonnet BioTherapeutics Holdings Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Sonnet BioTherapeutics Holdings's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Executives
John Markey 10 percent owner 10096 RIDGEWOOD DRIVE, TWINSBURG OH 44087
Susan Dexter officer: Chief Technical Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Albert D. Dyrness director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Nailesh Bhatt director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Pankaj Mohan director, officer: Chairman, President and CEO C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Lori Mcneill director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, SUITE 102, PRINCETON NJ 08540
Richard T Kenney officer: Chief Medical Officer C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Donald J. Griffith director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Terence Anthony Rugg officer: Chief Medical Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
John K. Cini officer: Chief Scientific Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Raghu Rao director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Cross John Harry Iii officer: Chief Financial Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Oz Rey Llc 10 percent owner 918 CONGRESS AVENUE, SUITE 100, AUSTIN TX 78701
Mv Amanth Llc 10 percent owner 515 CONGRESS AVE, STE 1400, AUSTIN TX 78701-3516
Robert Sumner Hersch 10 percent owner 515 CONGRESS AVE, STE 1400, AUSTIN TX 78701

Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Headlines

From GuruFocus